We believe that this work is timely in the emerging landscape of preventive trials for dementia in DS given that consideration of APOE genotype might be important for drugs that are designed to lower amyloid burden and/or trials that use MRI as a surrogate marker of improved outcomes. Here, APOE is linked to dementia.